(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Relive NASA's historic Artemis 2 launch to the moon in these stunning photos - 22024's Hot Games: Must-Play Titles of the Year
- 3UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 4A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- 56 Fledgling Cameras for 2024: Ideal for New Photographic artists
- South Africa collects record $117B tax haul
- 6 Agreeable Earphones To Wear
- UN warns civil liberties under threat due to war in Middle East
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- Hezbollah claims right to respond to killing of top commander
- Israel faces widespread condemnation as NGO ban comes into effect
- Daily Briefing: A bad flu season gets worse
